| Active substance | Amivantamab in combination with lazertinib |
| Holder | Janssen-Cilag NV |
| Status | Running |
| Indication | first line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 27/01/2026 |